Medico RemediesNSE:MEDICO +1.59%88 Return-on-Tangible-Equity is 31.05% as of Mar. 2026, which is 153% above its 10-year median of 12.27. GuruFocus rates NSE:MEDICO with a GF Score™ of 88/100 and a GF Value™ of ₹76.35 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 901 Drug Manufacturers companies, Medico Remedies ranks better than 78.02% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medico Remedies's annualized net income for the quarter that ended in Mar. 2026 was ₹234 Mil. Medico Remedies's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹754 Mil. Therefore, Medico Remedies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 31.05%.
The historical rank and industry rank for Medico Remedies's Return-on-Tangible-Equity or its related term are showing as below:
NSE:MEDICO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 5.61 Med: 12.27 Max: 19.23
Current: 19.23
During the past 13 years, Medico Remedies's highest Return-on-Tangible-Equity was 19.23%. The lowest was 5.61%. And the median was 12.27%.
NSE:MEDICO's Return-on-Tangible-Equity is ranked better than 78.02% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:MEDICO: 19.23
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medico Remedies Return-on-Tangible-Equity Related Terms
Medico Remedies Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medico Remedies's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MEDICO vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medico Remedies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medico Remedies Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medico Remedies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medico Remedies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 31.05% mean?
Medico Remedies (NSE:MEDICO) has a Return-on-Tangible-Equity of 31.05% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medico Remedies and its competitors. This is 153% above median its historical median of 12.27. Over the past decade, Medico Remedies' Return-on-Tangible-Equity has ranged from 5.61 to 19.23. According to the industry distribution chart, Medico Remedies ranks #198 out of 901 companies in the Drug Manufacturers industry, placing it in the top 22%.
Is Medico Remedies' Return-on-Tangible-Equity too high?
Medico Remedies' current Return-on-Tangible-Equity of 31.05% is 153% above median its 10-year median of 12.27. Over the past 10 years, this metric has ranged from a low of 5.61 to a high of 19.23. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Medico Remedies' value of 31.05% is 293% above this industry median. Based on the distribution chart, Medico Remedies ranks #198 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medico Remedies has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medico Remedies' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medico Remedies ranks #198 out of 901 companies for Return-on-Tangible-Equity. This places Medico Remedies in the top 22% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Medico Remedies' value of 31.05% is 293% above this benchmark. Historically, Medico Remedies' own Return-on-Tangible-Equity has ranged from 5.61 to 19.23 over the past decade. While the company's 10-year median is 12.27 vs. the industry median of 7.90, Medico Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medico Remedies's current Return-on-Tangible-Equity of 31.05% is 293% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medico Remedies and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medico Remedies's current Return-on-Tangible-Equity is 31.05%, which is 153% above median its own 10-year median of 12.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medico Remedies stock overvalued right now?
Based on GuruFocus' analysis, Medico Remedies (NSE:MEDICO) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹76.35, compared to a current price of ₹39.71 — trading 48% below its estimated fair value. The current Return-on-Tangible-Equity is 31.05%, which is 153% above median its 10-year median of 12.27 and 293% above the Drug Manufacturers industry median of 7.90. Medico Remedies' overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medico Remedies (NSE:MEDICO), the current Return-on-Tangible-Equity is 31.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medico Remedies (NSE:MEDICO) Overvalued in 2026?
Based on GuruFocus' analysis, Medico Remedies stock appears to be undervalued.
The current stock price of ₹39.71 is trading 48% below its estimated GF Value™ of ₹76.35.
GuruFocus considers Medico Remedies to be Significantly Undervalued.
Key valuation signals for NSE:MEDICO:
Return-on-Tangible-Equity: 31.05% (153% above median its 10-year median of 12.27)
GF Value™: ₹76.35 vs. price of ₹39.71 (48% below fair value)
Industry Position: 293% above the Drug Manufacturers median (#198 of 901)
No single metric tells the full story. See the NSE:MEDICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medico Remedies Ltd is a manufacturer, supplier, and exporter of pharmaceutical drugs. It operates in single segment single segment of manufacturing medicines including Antihy pertensive Antidiabetics Antibictics Diuretics, Antimalarials, NSAIDS Tablets, Antireterovirals, Anti-Ulcer Drugs and Antacids Tablets, so many drugs used for treatment of so many diseases for oral use as well as external preparations like creams & ointments which includes anti infectives ,antifungals ,antibiotics ,steroidal preparations etc. In addition, it also sells other drugs such as antihistaminic, antidiabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments.
88GF Score
Get the complete analysis for NSE:MEDICO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDICO has been successfully added to your 
